ArticleToxicology and applied pharmacology2019
Identification of differentially expressed genes and networks related to hepatic lipid dysfunction.
Article in Toxicology and applied pharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 3 citations in OpenAlex.
- Computational Strategies for Assessing Adverse Outcome Pathways: Hepatic Steatosis as a Case Study.International journal of molecular sciences · 2024Review
- Modernization of chemical risk assessment to make use of novel toxicological data.Toxicology and applied pharmacology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
A range of chemical exposures that resulted in the specific pathology of hepatic lipid dysfunction in rats were selected from DrugMatrix, a publicly available toxicogenomic database. Raw microarray data collected from these exposures were further analyzed using bioinformatic tools to generate a differentially expressed genes (DEGs) dataset associated with hepatic lipid dysfunction. Further analysis of the DEGs dataset resulted in 324 upregulated genes, and 275 genes that were down regulated. Meanwhile, 36 genes were either up regulated or down regulated in different chemical treatments. All identified genes were uploaded in the web application for Database for Annotation, Visualization and Integrated Discovery (DAVID) for gene ontology enrichments and to identify Kyoto Encyclopedia of Genes and Genome (KEGG) pathways. Some of the identified pathways included glycolysis/gluconeogenesis, steroid hormone biosynthesis, retinol metabolism, and metabolism of xenobiotics by cytochrome P450. The same DEGs dataset was also analyzed using Ingenuity Pathway Analysis (IPA) software. IPA identified several pathways including PXR/RXR activation, Aryl hydrocarbon receptor signaling, and xenobiotic metabolism signaling. Furthermore, the generated DEGs lists were uploaded into NCATS BioPlanet platform. Some of the identified pathways were related to fatty acid omega oxidation, lipid and lipoprotein metabolism, and adipogenesis. The enrichment and clarification of the pathways and biological networks obtained from the DEGs dataset provide prior knowledge on the underlying biological key events and molecular mechanisms for the computational development of putative adverse outcome pathways (AOPs) for hepatic lipid dysfunction as a precursor to hepatic steatosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.